MEDIVIR, INTERIM REPORT, 1 January

MEDIVIR, INTERIM REPORT, 1 January - 31 March 2008

• Consolidated net sales were SEK 4.2 (53.3) m. 
• The loss after tax amounted to SEK -41.2 (-25.6) m. 
• Earnings per share amounted to SEK -1.98 (-1.52) m.
• Cash flow from operating activities increased by SEK 29.1 m to SEK -5.5
(-34.6) m. Liquid assets amounted to SEK 323.5 (369.8) m as of 31 March. 


CEO's statement—comments on the first quarter

We published the results from our phase III program on Lipsovir® — a potential
labial herpes pharmaceutical — in the quarter. The results demonstrated that it
is possible to prevent cold sores by early treatment initiation with Lipsovir®.
None of the products currently on the market have been able to demonstrate this
effect. This is an important milestone for Medivir, and these results will now
be presented to regulatory authorities ahead of future filings for registration.
In parallel, we are continuing our discussions with potential marketing
partners.

Our other prioritized projects also progressed well in the quarter. We extended
our collaboration with Tibotec on HIV protease inhibitors, and our hepatitis C
collaboration project, TMC-435350, is making good progress in its phase IIa
study.

After the end of the reporting period, Medivir entered into a collaboration with
GlaxoSmithKline, which gives Medivir the rights to market selected GSK products
in Sweden. This is a significant first step in the work on establishing Medivir
as a pharmaceutical company on the Nordic market.


Lars Adlersson
CEO

Huddinge, Sweden, 23 April 2008


FOR MORE INFORMATION, PLEASE CONTACT:
Rein Piir, CFO and VP, Investor Relations: +46 (0)8 546 83123 or +46 (0)70 853
7292.

FORTHCOMING FINANCIAL INFORMATION
The Annual General Meeting will be held today at 3 p.m.
The Six-month Interim Report will be published on 9 July 2008.
The Nine-month Interim Report will be published on 20 October 2008.

These reports will be available at Medivir's Website, www.medivir.se from these
dates under the ‘Investor/Media' heading.
MEDIVIR, INTERIM REPORT, 1 January - 31 March 2008

Attachments
